Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

BACKGROUND AND OBJECTIVE: Gilteritinib is a novel, highly selective tyrosine kinase inhibitor approved in the USA, Canada, Europe, Brazil, Korea, and Japan for the treatment of FLT3 mutation-positive acute myeloid leukemia. This article describes the clinical pharmacokinetic profile of gilteritinib....

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Pharmacokinet
Autores principales: James, Angela Joubert, Smith, Catherine C., Litzow, Mark, Perl, Alexander E., Altman, Jessica K., Shepard, Dale, Kadokura, Takeshi, Souda, Kinya, Patton, Melanie, Lu, Zheng, Liu, Chaofeng, Moy, Selina, Levis, Mark J., Bahceci, Erkut
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7550323/
https://ncbi.nlm.nih.gov/pubmed/32304015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-020-00888-w
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares